Yttrium-90 radioembolization for neuroendocrine liver metastases: baseline vascularity predicts cytoreduction efficacy
PLOS One · 14.07.2026 · 21 (7) · e0352018
DOI: 10.1371/journal.pone.0352018 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 14.07.2026. Verfasst von Anne Frisch und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology, Medizinische Fakultät Ostwestfalen Lippe, Bielefeld, Germany. Hauptthemen laut MEDLINE: Liver Neoplasms, Yttrium Radioisotopes, Radioembolization, Therapeutic, Neuroendocrine Tumors. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This retrospective study in patients with neuroendocrine liver metastases analyzes baseline vascularity on MR as a predictor of tumour debulking after conventional Yttrium-90 transarterial radioembolization (TARE).
Methods
30 patients who underwent TARE at our center between 2015 and 2022 were retrospectively assessed. Pre- and post-treatment target lesion volumes were measured as total tumor volume (TTV) and enhancing tumor volume (ETV). Cox-regression analyses as well as Kaplan-Meier statistics were used to evaluate baseline volumetric imaging parameters and clinical variables as predictors of survival.
Results
Mean patients’ age was 63 (SD 11) years, 15 were female (50%). The primary tumor was in the upper gastrointestinal tract in 13/30 cases (43%). Median overall survival (mOS) was 33.0 months (95%CI [21.2; 44.7]). Eligibility for peptide receptor radionuclide therapy (PRRT) was the single strongest predictor of survival with a hazard ratio of 0.22 (p = 0.024) and a mOS of 60.8 months whereas receptor-negative patients had the shortest survival of 7.0 months (p = 0.019). A baseline ETV/TTV ratio greater 50% was associated with a decrease in median ETV by 41% after lobar TARE compared to an increase by 18% in patients with poor baseline vascularity (p = 0.018). In the 17/30 patient who received systemic therapies exclusively before TARE, mOS was 15 vs. 6.8 months (p = 0.082). Prior PRRT did not significantly impact the change of ETV after TARE.
Conclusion
In lobar TARE for neuroendocrine liver metastases, high baseline vascularity shows an exploratory association with a significant reduction in viable tumor volume, warranting further investigation to improve patient selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic and Interventional Radiology, Medizinische Fakultät Ostwestfalen Lippe, Bielefeld, Germany.
- Department of Diagnostic and Interventional Radiology, Health and Medical University Potsdam, Potsdam, Germany.
- Department of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Department of Radiology, Medizinische Universität Lausitz - Carl Thiem, Cottbus, Germany.
ORCID-Profile: Willie M Lüdemann
Zitieren
APA
Frisch, A., Kahn, J., Collettini, F., Steinhagen, P., Fehrenbach, U., Gebauer, B., Amthauer, H., Schatka, I., Herzler, P., Wieners, G., & Lüdemann, W. M. (2026). Yttrium-90 radioembolization for neuroendocrine liver metastases: baseline vascularity predicts cytoreduction efficacy. PLOS One, 21(7), e0352018. https://doi.org/10.1371/journal.pone.0352018
Vancouver
Frisch A, Kahn J, Collettini F, Steinhagen P, Fehrenbach U, Gebauer B, et al. Yttrium-90 radioembolization for neuroendocrine liver metastases: baseline vascularity predicts cytoreduction efficacy. PLOS One. 2026;21(7):e0352018. doi:10.1371/journal.pone.0352018
BibTeX
@article{Frisch2026,
author = {Frisch, Anne and Kahn, Johannes and Collettini, Federico and Steinhagen, Peter and Fehrenbach, Uli and Gebauer, Bernhard and Amthauer, Holger and Schatka, Imke and Herzler, Paul and Wieners, Gero and Lüdemann, Willie M},
title = {Yttrium-90 radioembolization for neuroendocrine liver metastases: baseline vascularity predicts cytoreduction efficacy},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0352018},
doi = {10.1371/journal.pone.0352018}
}
EUVIMED